<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01366352</url>
  </required_header>
  <id_info>
    <org_study_id>MNTX 1202</org_study_id>
    <nct_id>NCT01366352</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets</brief_title>
  <official_title>Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets: A Double-Blind, Single Dose, Crossover, Phase 1 Study in Normal Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a single-center, double-blind, randomized, cross-over Phase 1 study in normal,
      healthy volunteers. Study treatment entailed single doses of two different formulations of
      MNTX tablets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of MNTX administered as two different oral formulations</measure>
    <time_frame>7 days</time_frame>
    <description>To determine and compare the plasma pharmacokinetics and extent of single, oral doses of two different oral formulations of MNTX in normal healthy volunteers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Half-life of MNTX administered as two different oral formulations</measure>
    <time_frame>7 days</time_frame>
    <description>To determine and compare the plasma pharmacokinetics and extent of single, oral doses of two different oral formulations of MNTX in normal healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from a single dose to maximum concentration (Tmax) of MNTX administered as two different oral formulations</measure>
    <time_frame>7 days</time_frame>
    <description>To determine and compare the plasma pharmacokinetics and extent of single, oral doses of two different oral formulations of MNTX in normal healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration (AUC) of MNTX administered as two different oral formulations</measure>
    <time_frame>7 days</time_frame>
    <description>To determine and compare the plasma pharmacokinetics and extent of single, oral doses of two different oral formulations of MNTX in normal healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance over bioavailability (CL/F) of MNTX administered as two different oral formulations</measure>
    <time_frame>7 days</time_frame>
    <description>To determine and compare relative bioavailability, and extent of single, oral doses of two different oral formulations of MNTX in normal healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution over bioavailability (V/F) of MNTX administered as two different oral formulations</measure>
    <time_frame>7 days</time_frame>
    <description>To determine and compare the plasma pharmacokinetics, relative bioavailability, and extent of single, oral doses of two different oral formulations of MNTX in normal healthy volunteers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Normal Volunteers</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MNTX tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MNTX tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MNTX tablet (Formulation 1)</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MNTX tablet (Formulation 2)</intervention_name>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Weight between 55 and 85 kg

          2. In good health, based on history, physical examination, and appropriate laboratory and
             diagnostic tests at screening, with no evidence of clinically significant chronic
             medical condition

          3. Non-smokers.

        Exclusion Criteria:

          1. History of evidence of cardiovascular, gastrointestinal, hepatic, musculoskeletal,
             neurological, pulmonary, renal, or other significant chronic illness

          2. History of asthma, allergic skin rash, significant allergy, or other immunologic
             disorder

          3. Consumption of barbiturates or other inducers or inhibitors of CYP450

          4. History or suspicion of alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tage Ramakrishna, MD</last_name>
    <role>Study Director</role>
    <affiliation>Progenics Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Progenics Pharmaceuticals, Inc.</name>
      <address>
        <city>Tarrytown</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2011</study_first_posted>
  <last_update_submitted>July 17, 2011</last_update_submitted>
  <last_update_submitted_qc>July 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tage Ramakrishna, MD</name_title>
    <organization>Progenics Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylnaltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

